| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002066739 |
| P356 | DOI | 10.1186/1758-5996-6-42 |
| P932 | PMC publication ID | 3998187 |
| P698 | PubMed publication ID | 24650557 |
| P5875 | ResearchGate publication ID | 260995477 |
| P50 | author | Flávio Reis | Q38545312 |
| Helena Vala | Q47352510 | ||
| Rosa Fernandes | Q47503161 | ||
| Paulo Rodrigues-Santos | Q50880687 | ||
| Jorge Oliveira | Q59675095 | ||
| Edite Teixeira De Lemos | Q64190488 | ||
| P2093 | author name string | Cristina Mega | |
| Edite Teixeira de Lemos | |||
| P2860 | cites work | NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE | Q76819524 |
| Tribbles homologue 3 (TRIB3) and the insulin-resistance genes in type 2 diabetes | Q84453183 | ||
| Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats | Q84959531 | ||
| Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes | Q24534395 | ||
| Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin | Q24642412 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| The mammalian tribbles homolog TRIB3, glucose homeostasis, and cardiovascular diseases | Q27002724 | ||
| The functional Q84R polymorphism of mammalian Tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy | Q28269098 | ||
| Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
| The entero-insular axis: implications for human metabolism. | Q30365939 | ||
| Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. | Q30368546 | ||
| Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives | Q31121965 | ||
| Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes | Q33209301 | ||
| The role of TNFalpha and TNF receptors in obesity and insulin resistance | Q33680471 | ||
| Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance | Q33727391 | ||
| Gliptins: a new class of oral antidiabetic agents | Q33757148 | ||
| The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes | Q33826388 | ||
| The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus | Q33891620 | ||
| Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) | Q34003019 | ||
| Control of adipose tissue inflammation through TRB1. | Q34024348 | ||
| Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity | Q34109834 | ||
| Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. | Q34589793 | ||
| Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective | Q34675820 | ||
| Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney | Q34690495 | ||
| The interleukin-6 and noradrenaline mediated inflammation-stress feedback mechanism is dysregulated in metabolic syndrome: effect of exercise. | Q35054609 | ||
| Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). | Q35607330 | ||
| Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes | Q35838612 | ||
| Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans | Q35844598 | ||
| Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes | Q35961969 | ||
| Type 2 diabetes: principles of pathogenesis and therapy | Q36095054 | ||
| The TRIB3 Q84R polymorphism and risk of early-onset type 2 diabetes | Q37072688 | ||
| Signal transduction mechanism of TRB3 in rats with non-alcoholic fatty liver disease | Q37198294 | ||
| TRIB3 functional Q84R polymorphism is a risk factor for metabolic syndrome and carotid atherosclerosis | Q37235837 | ||
| The incretin system and its role in type 2 diabetes mellitus | Q37266863 | ||
| A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas | Q37267313 | ||
| Incretin-based therapies: viewpoints on the way to consensus | Q37624267 | ||
| Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies | Q37650996 | ||
| The beta-cell in human type 2 diabetes. | Q37706253 | ||
| Role of IL-1beta in type 2 diabetes | Q37768631 | ||
| Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes | Q37864214 | ||
| Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research | Q38040596 | ||
| Extra-pancreatic effects of incretin-based therapies | Q38194069 | ||
| The incretin concept today | Q39227026 | ||
| Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice | Q39797395 | ||
| High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes | Q40137823 | ||
| Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes | Q40176269 | ||
| A radical explanation for glucose-induced beta cell dysfunction | Q40348848 | ||
| Hyperglycemia-induced production of acute phase reactants in adipose tissue | Q40781707 | ||
| New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins | Q42078124 | ||
| Vildagliptin preserves the mass and function of pancreatic β cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes | Q43070817 | ||
| Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas | Q43276184 | ||
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
| Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin | Q43920022 | ||
| Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. | Q44193794 | ||
| The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes | Q44386674 | ||
| Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats | Q46210455 | ||
| The [pre-] history of the incretin concept | Q46393857 | ||
| Overexpression of TRB3 gene in adipose tissue of rats with high fructose-induced metabolic syndrome | Q46581204 | ||
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | Q46804059 | ||
| Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin | Q51333357 | ||
| A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. | Q51350351 | ||
| Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice | Q51364785 | ||
| Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 | ||
| Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes | Q52574567 | ||
| Reduced Incretin Effect in Type 2 Diabetes | Q58168459 | ||
| Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects | Q58449089 | ||
| Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model | Q61952011 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 42 | |
| P577 | publication date | 2014-03-20 | |
| P1433 | published in | Diabetology and Metabolic Syndrome | Q15816649 |
| P1476 | title | Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties | |
| P478 | volume | 6 |
| Q64898328 | DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates β-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice. |
| Q36639293 | DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid |
| Q42319765 | Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study |
| Q46254755 | Ephedrine as a lead compound for the development of new DPP-IV inhibitors. |
| Q34344972 | Immuno-modulator metallo-Peptide reduces inflammatory state in obese zucker fa/fa rats |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q48270894 | Sitagliptin Attenuates Endothelial Dysfunction of Zucker Diabetic Fatty Rats: Implication of the Antiperoxynitrite and Autophagy |
| Q38941094 | Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes |
| Q92282014 | The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin |
| Q38820260 | The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond |
| Q61814333 | Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes |
Search more.